Healthcare / Medical DevicesNasdaqCM
$7.95
+0.01 (+0.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-20.7M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$22M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-236.8%
↓Gross Margin
38.2%
↓Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
+24.5%
FCF CAGR
—
FCF margin
-76.4%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.0M · net income $-19.9M · FCF $-16.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $22.0M | $22.0M | $25.7M | $13.9M | $5.5M | $432000.00 | $330000.00 | $4.9M | $6.5M | $135000.00 | $5.9M | $3.7M | $4.0M | $1.6M |
| Net Income | $-19.9M | $-19.9M | $-28.9M | $-22.1M | $-19.6M | $-12.7M | $-13.0M | $-15.6M | $-21.7M | $-24.7M | $-32.5M | $-25.4M | $-21.7M | $-12.2M |
| EBITDA | $-16.6M | $-16.6M | $-15.7M | $-21.8M | $-18.9M | — | — | — | — | $-21.4M | $-29.7M | $-24.7M | $-19.8M | $-8.7M |
| EPS | -17.16 | -17.16 | -39.96 | -31.13 | -26.35 | -22.68 | -68.88 | — | — | — | — | — | — | — |
| Gross Margin | 38.2% | 38.2% | 32.0% | 32.1% | 34.6% | 672.0% | 663.3% | 55.9% | 43.2% | 2297.0% | 12.5% | 5.7% | -15.7% | -27.0% |
| Operating Margin | -76.7% | -76.7% | -76.2% | -170.4% | -346.6% | -2929.4% | -3637.6% | -288.3% | -293.6% | -16290.4% | -518.7% | -672.0% | -504.3% | -550.7% |
| Net Margin | -90.4% | -90.4% | -112.8% | -159.8% | -355.1% | -2948.1% | -3932.1% | -319.1% | -331.2% | -18308.9% | -553.8% | -678.5% | -548.4% | -766.8% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.52 | 0.52 | 0.05 | 0.04 | 0.01 | — | — | 0.14 | 3.58 | 2.40 | 1.27 | 0.00 | — | — |
| Current Ratio | 2.40 | 2.40 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-16.8M | $-16.8M | $-21.7M | $-20.7M | $-17.9M | $-11.5M | $-12.7M | $-14.8M | $-14.8M | $-22.5M | $-27.2M | — | — | — |
| Returns | ||||||||||||||
| ROE | -236.8% | -236.8% | -153.5% | -47.6% | -28.7% | -14.2% | -59.6% | -144.3% | -1114.4% | -666.8% | -393.5% | -121.5% | -49.4% | -216.2% |
| Valuation | ||||||||||||||
| P/B | 1.10 | 1.10 | 1.23 | 1.59 | 0.76 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -14.1% | -14.1% | 85.2% | 151.4% | — | 30.9% | -93.2% | -25.5% | 4748.1% | -97.7% | 56.7% | -5.2% | 148.8% | — |
| EPS Growth | 57.1% | 57.1% | -28.4% | -18.1% | — | 67.1% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-39.96 → -17.16
Residual
-46.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.